Northpond Ventures III GP, LLC sold KYTX

February 12, 2024 · Form 4 insider transaction

Northpond Ventures III GP, LLC sold 12,767,776 shares of Kyverna Therapeutics, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.

Direction
Disposed (sell-side)
Shares
12,767,776
Price
N/A
Total value
N/A
Role
SecuritySeries B Preferred Stock
Transaction codeC: Conversion of a derivative
Transaction dateFebruary 12, 2024
Filing dateFebruary 12, 2024
Shares owned after0
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the "Issuer"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the "Series B Preferred Stock"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the "Common Stock"). The Series B Preferred Stock had no expiration date.; Northpond Ventures III GP, LLC ("Northpond III LLC") is the general partner of Northpond Ventures III, LP ("Northpond Fund III"), and Michael P. Rubin is the managing member of Northpond III LLC. As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

View the original Form 4 on SEC EDGAR